ACS CAN Supports the DIVERSE Trials Act (H.R. 5030/S. 2706)
The DIVERSE Trials Act (H.R. 5030/S. 2706) could increase racial, socioeconomic and geographic diversity in clinical trials and make it easier for all cancer patients to participate.
In a recent poll, 51% of cancer patients and survivors report incurring medical debt as a result of their cancer care. Of those patients, 45% have delayed or avoided medical care for serious issues as a result of the debt they incurred. As Congress considers budget reconciliation legislation, ACS CAN urges lawmakers to help cancer patients and survivors with significant and rising cancer care costs by: